New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
09:07 EDTRGLSRegulus Therapeutics initiated with an Outperform at Brinson Patrick
Target $16.
News For RGLS From The Last 14 Days
Check below for free stories on RGLS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2014
08:18 EDTRGLSRegulus Therapeutics granted orphan drug designation for RG-012 by FDA
Regulus Therapeutics announced that the FDA has granted orphan drug designation to RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21, as a therapeutic for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy. In the near term, Regulus expects to initiate a natural history of disease study to gather further information about the progression of Alport syndrome and to inform future clinical development plans of RG-012, a key program under Regulus' 'Clinical Map Initiative'.
July 18, 2014
15:04 EDTRGLSWedbush reiterates Outperform rating on Regulus after orphan designation
Subscribe for More Information
11:05 EDTRGLSRegulus Therapeutics treatment of Alport syndrome designated as orphan drug
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use